Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acalabrutinib + R-CHOP
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**acalabrutinib + R-CHOP** is a combination therapy regimen used in clinical research for B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL). It consists of acalabrutinib—a second-generation, highly selective covalent Bruton tyrosine kinase (BTK) inhibitor—and the established R-CHOP regimen, which includes rituximab (monoclonal anti-CD20 antibody), cyclophosphamide (alkylating agent), doxorubicin (anthracycline), vincristine (vinca alkaloid), and prednisolone (corticosteroid)[1][3][7]. Acalabrutinib inhibits BTK to interfere with B-cell receptor (BCR) signaling, while R-CHOP acts through multiple cytotoxic and immunological mechanisms targeting dividing B-cells[2][4][6]. The rationale for this combination is to enhance efficacy by simultaneously inhibiting BCR signaling and cytotoxicly targeting malignant B cells[3][5].
- Brand names
- Calquence
- Other names
- acalabrutinib and R-CHOPacalabrutinib plus R-CHOP
02
Targets
CD20 (B-lymphocyte antigen CD20)ERBB4 (Erb-b2 receptor tyrosine kinase 4)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))BMX (Bone Marrow Tyrosine Kinase X-linked)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on acalabrutinib + R-CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acalabrutinib + R-CHOP.